Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy;Langfristig wirksame zweit-therapie der HIV-infektion bei klassenwechsel nach virologischem Versagen unter protease-inhibitoren

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 23, 2010, Pages 1166-1170

  Brunner, J ^a   Seybold, U ^a   Gunsenheimer Bartmeyer, B ^b   Hamouda, O ^b   Bogner, J R ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Drug class switch; HIV treatment; Modified antiretroviral treatment; Second line therapy; Virological failure

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR;

ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GERMANY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; GERMANY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; KAPLAN-MEIERS ESTIMATE; LONG-TERM CARE; MALE; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 77953171597     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1255124     Document Type: Article

References (15)

1. Antinori A, Zaccarelli M, Cingolani A et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002 18 835-838
2. Barreiro P, Soriano V, Blanco F et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000 14 807-812
3. Black N. Why we need observational studies to evaluate the effectiveness of health care. Br Med J 1996 312 1215-1218
4. Clumeck N, Dedes N, Pozniak A, Raffi F, the EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults, version 5, Nov 2009. http://www. europeanaidsclinicalsociety.org/guidelinespdf/1-Treatment-of-HIV-Infected- Adults.pdf
5. Grennan T, Walmsley S. Etravirine for HIV-I: Addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class. J Int Assoc Physicians AIDS Care (Chic Ill) 2009 8 354-363
6. Hamouda O, Marcus U, Voß L, Kollan C. Verlauf der HIV-Epidemie in Deutschland. Bundesgesundheitsblatt 2007 50 399-411
7. Kollan C, Kühne A, Bartmeyer B, Hamouda O. Aktuelle Antiretrovirale Behandlungspraxis. Ergebnisse der multizentrischen ClinSurv-Studie. Deutsch-österreichische-Schweizerischer AIDS-Kongress 2009. St Gallen 2008
8. Losina E, Islam R, Pollock A C. et al. Effectiveness of Antiretroviral therapy after protease inhibitor failure. Clin Infect Dis 2004 38 1613-1622
9. Mills A M., Nelson M et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients. Aids 2009 23 1679-1688
10. Molina J M., Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients. Lancet 2008 372 646-655
11. Riddler S A., Haubrich R, DiRienzo A G. et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008 358 2095-2106
12. Robert-Koch-Institut. Zum Verlauf der HIV-Epidemie in Deutschland bis Ende 2009. Epidemiologisches Bulletin 2009 491-492
13. Soriano V, Köppe S, Mingrone H et al. Prospective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatment-nave HIV-1 infected patients: ARTEN study week 48 results. Cape Town, South Africa IAS 2009 2009
14. Sungkanuparph S, Manosuthi W, Kiertiburanakul S et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007 44 447-452
15. Vo T T., Ledergerber B, Keiser O et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008 197 1685-1694